文献速递类风湿关节炎脊柱关节炎

接受改善病情抗风湿药治疗的慢性炎症性风湿病患者对SARS-CoV-2的适应性免疫应答

Adaptive immune responses to SARS-CoV-2 in DMARD-treated patients with chronic inflammatory rheumatisms.
PubMed 文献 · RMD Open · 2025-07-05

本研究纳入94例确诊SARS-CoV-2感染的类风湿关节炎和脊柱关节炎患者及20例年龄匹配的家庭接触者作为对照,评估免疫调节治疗对适应性免疫应答的影响。结果显示接受免疫调节治疗的患者未出现病毒持续存在,整体体液和T细胞应答保留,但利妥昔单抗治疗与较低的IgA、IgG应答及减少的SARS-CoV-2特异性活化CD8+T细胞相关。

要点

  • 接受免疫调节治疗的患者血液、鼻咽和粪便中未观察到病毒持续存在。
  • 利妥昔单抗组SARS-CoV-2特异性IgA和IgG应答显著低于其他治疗组。
  • 利妥昔单抗治疗与SARS-CoV-2特异性活化CD8+T细胞减少相关。

核心结论

  • 大多数患者能够产生针对SARS-CoV-2的免疫应答,但利妥昔单抗治疗影响了体液和CD8+细胞应答。
  • 开发能引发强效CD8+T细胞应答的疫苗可能对接受免疫调节治疗的炎症性风湿病患者有益。

研究设计与样本

  • 研究纳入94例确诊SARS-CoV-2感染的患者(48例脊柱关节炎,46例类风湿关节炎,平均年龄53±14岁),按治疗分组:甲氨蝶呤/柳氮磺吡啶(17/2例)、抗TNF(24例)、抗TNF+甲氨蝶呤(23例)、利妥昔单抗(11例)、抗IL-17(7例)和其他(11例)。
  • 纳入20例年龄匹配(50±17岁)且同时感染的家庭接触者作为对照人群。
  • 比较血浆、粪便和鼻拭子中的病毒载量以及SARS-CoV-2特异性体液和细胞免疫应答(抗体、B和T淋巴细胞)。

主要发现

  • 接受免疫调节治疗的患者血液、鼻咽和粪便中未观察到病毒持续存在。
  • 整体SARS-CoV-2特异性体液和T细胞应答保留。
  • 接受利妥昔单抗的患者SARS-CoV-2特异性IgA和IgG应答显著低于其他治疗组。
  • 大多数患者(包括利妥昔单抗接受者)表现出显著的CD4+T细胞应答。
  • 利妥昔单抗治疗与SARS-CoV-2特异性活化CD8+T细胞减少相关,且观察到体液免疫参数与CD8+T细胞活化之间的相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) are at an increased risk for infection related to the use of immunomodulatory therapies (ITs). The objective of this study is to assess the impact of ITs on the adaptive immune responses to SARS-CoV-2. METHODS: The study population comprised 94 patients (48 SpA; 46 RA; mean age of 53±14 years) with a confirmed SARS-CoV-2 infection. 20 age-matched individuals (50±17 years), corresponding to the patients' household contacts infected at the same time, were included as the control population. Patients were stratified by treatment groups: methotrexate (MTX)/sulfasalazine (n=17/2), anti-TNF (n=24), anti-TNF+MTX (n=23), RTX (N=11), anti-IL17 (n=7) and others (n=11). The study compared the viral loads in plasma, stools and nasal swabs and the SARS-CoV-2-specific humoral and cellular immune responses (antibodies, B and T lymphocytes) following SARS-CoV-2 infection. RESULTS: Viral persistence was not observed in the blood, nasopharynx and stools of patients undergoing ITs. Overall, the SARS-CoV-2-specific humoral and T-cell responses were preserved. Patients receiving RTX showed significantly lower IgA and IgG responses to SARS-CoV-2 compared with other treatment groups. Most patients, including RTX recipients, exhibited significant CD4+T cell responses. However, RTX therapy was associated with reduced SARS-CoV-2-specific activated CD8+T cells. A correlation was observed between humoral immune parameters and CD8+ T cell activation. CONCLUSIONS: While most patients demonstrated the capacity to mount an immune response to SARS-CoV-2, treatment with RTX impacted both humoral and CD8+cell responses. Developing vaccines that elicit robust CD8+T cell responses could offer benefits to individuals undergoing ITs for inflammatory rheumatic diseases.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Beretta M, Martin E, Fogel O, et al. Adaptive immune responses to SARS-CoV-2 in DMARD-treated patients with chronic inflammatory rheumatisms. RMD Open. 2025. PMID: 40617588. doi:10.1136/rmdopen-2025-005673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。